Pardeshi Rohit, Bolshette Nityanand, Gadhave Kundlik, Arfeen Mohammad, Ahmed Sahabuddin, Jamwal Rohitash, Hammock Bruce D, Lahkar Mangala, Goswami Sumanta Kumar
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College and Hospital, Guwahati, India.
Institutional Level Biotech Hub (IBT Hub), Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College and Hospital, Guwahati, India.
Front Pharmacol. 2019 Apr 24;10:288. doi: 10.3389/fphar.2019.00288. eCollection 2019.
Diabetes is a risk factor for Alzheimer's disease and it is associated with significant memory loss. In the present study, we hypothesized that the soluble epoxide hydrolase (sEH) inhibitor N-[1-(1-oxopropyl)-4-piperidinyl]-N'-[4-(trifluoromethoxy)phenyl)-urea (also known as TPPU) could alleviate diabetes-aggravated Alzheimer's disease-like symptoms by improving memory and cognition, and reducing the oxidative stress and inflammation associated with this condition. Also, we evaluated the effect of edaravone, an antioxidant on diabetes-induced Alzheimer's-like complications and the additive effect of docosahexaenoic acid (DHA) on the efficacy of TPPU. Diabetes was induced in male Sprague-Dawley rats by intraperitoneally administering streptozotocin (STZ). Six weeks after induction of diabetes, animals were either treated with vehicle, edaravone (3 or 10 mg/kg), TPPU (1 mg/kg) or TPPU (1 mg/kg) + DHA (100 mg/kg) for 2 weeks. The results demonstrate that the treatments increased the memory response of diabetic rats, in comparison to untreated diabetic rats. Indeed, DHA + TPPU were more effective than TPPU alone in reducing the symptoms monitored. All drug treatments reduced oxidative stress and minimized inflammation in the brain of diabetic rats. Expression of the amyloid precursor protein (APP) was increased in the brain of diabetic rats. Treatment with edaravone (10 mg/kg), TPPU or TPPU + DHA minimized the level of APP. The activity of acetylcholinesterase (AChE) which metabolizes acetylcholine was increased in the brain of diabetic rats. All the treatments except edaravone (3 mg/kg) were effective in decreasing the activity of AChE and TPPU + DHA was more efficacious than TPPU alone. Intriguingly, the histological changes in hippocampus after treatment with TPPU + DHA showed significant protection of neurons against STZ-induced neuronal damage. Overall, we found that DHA improved the efficacy of TPPU in increasing neuronal survival and memory, decreasing oxidative stress and inflammation possibly by stabilizing anti-inflammatory and neuroprotective epoxides of DHA. In the future, further evaluating the detailed mechanisms of action of sEH inhibitor and DHA could help to develop a strategy for the management of Alzheimer's-like complications in diabetes.
糖尿病是阿尔茨海默病的一个风险因素,且与显著的记忆丧失有关。在本研究中,我们假设可溶性环氧化物水解酶(sEH)抑制剂N-[1-(1-氧代丙基)-4-哌啶基]-N'-[4-(三氟甲氧基)苯基]脲(也称为TPPU)可通过改善记忆和认知、减轻与该病症相关的氧化应激和炎症,来缓解糖尿病加重的阿尔茨海默病样症状。此外,我们评估了抗氧化剂依达拉奉对糖尿病诱导的阿尔茨海默病样并发症的影响,以及二十二碳六烯酸(DHA)对TPPU疗效的增效作用。通过腹腔注射链脲佐菌素(STZ)诱导雄性Sprague-Dawley大鼠患糖尿病。糖尿病诱导六周后,动物分别接受赋形剂、依达拉奉(3或10mg/kg)、TPPU(1mg/kg)或TPPU(1mg/kg)+DHA(100mg/kg)治疗两周。结果表明,与未治疗的糖尿病大鼠相比,这些治疗增加了糖尿病大鼠的记忆反应。事实上,DHA+TPPU在减轻所监测症状方面比单独使用TPPU更有效。所有药物治疗均减轻了糖尿病大鼠大脑中的氧化应激并将炎症降至最低。糖尿病大鼠大脑中淀粉样前体蛋白(APP)的表达增加。依达拉奉(10mg/kg)、TPPU或TPPU+DHA治疗可使APP水平降至最低。在糖尿病大鼠大脑中,代谢乙酰胆碱的乙酰胆碱酯酶(AChE)活性增加。除依达拉奉(3mg/kg)外,所有治疗均能有效降低AChE活性,且TPPU+DHA比单独使用TPPU更有效。有趣的是,TPPU+DHA治疗后海马体的组织学变化显示神经元对STZ诱导的神经元损伤有显著保护作用。总体而言,我们发现DHA可能通过稳定DHA的抗炎和神经保护环氧化物,提高了TPPU在增加神经元存活和记忆、减轻氧化应激和炎症方面的疗效。未来,进一步评估sEH抑制剂和DHA的详细作用机制可能有助于制定一种治疗糖尿病中阿尔茨海默病样并发症的策略。